JS Capital Management’s 10x Genomics TXG Stock Holding History

JS Capital Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-540,589	Closed	-$80.5M	–	36
2021 Q4	$80.5M	Hold	540,589	–	–	3.66%	3
2021 Q3	$78.7M	Hold	540,589	–	–	4.56%	3
2021 Q2	$106M	Buy	540,589 +23,333	+5%	+$4.22M	5.12%	3
2021 Q1	$93.6M	Sell	517,256 -82,191	-14%	-$14.2M	4.84%	4
2020 Q4	$84.9M	Sell	599,447 -6,953	-1%	-$1.01M	4.06%	5
2020 Q3	$75.6M	Sell	606,400 -456,363	-43%	-$47.9M	3.91%	5
2020 Q2	$94.9M	Sell	1,062,763 -350,682	-25%	-$27.3M	7.17%	4
2020 Q1	$88.1M	Sell	1,413,445 -261,335	-16%	-$20.4M	11.08%	2
2019 Q4	$128M	Sell	1,674,780 -2,500	-0.1%	-$150K	14.71%	2
2019 Q3	$84.5M	Buy	+1,677,280	New	+$92.8M	11.51%	2

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JS Capital Management's TXG Position: Q1 2022 in Review

JS Capital Management sold out of 10x Genomics (TXG) in Q1 2022, closing a stake of 540,589 shares — an estimated $80.5M sold.

JS Capital Management first reported a position in TXG in Q3 2019 and held it in 10 quarters. The position peaked at $128M in Q4 2019. 314 funds tracked by Wall St. Rank hold TXG as of Q1 2022.

JS Capital Management reported no remaining 10x Genomics position as of Q1 2022 after selling out during the quarter.
JS Capital Management sold 540,589 10x Genomics shares in Q1 2022, an estimated $80.5M.
JS Capital Management first reported a position in 10x Genomics in Q3 2019 and held it in 10 quarters.
JS Capital Management's 10x Genomics position peaked at $128M in Q4 2019.
314 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2022.

Based on JS Capital Management's 13F filing for Q1 2022, filed 16 May 2022.